Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colleen C Nelson

Showing results (41-50 of 115) with videos related to

Pageof 12
Sort By:
Oncotarget|October 15, 2014
The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate cancerMartin C Sadowski, Rebecca H Pouwer, Jennifer H Gunter, et al.
International Journal of Pharmaceutics|September 17, 2017
Folate-targeted amphiphilic cyclodextrin nanoparticles incorporating a fusogenic peptide deliver therapeutic siRNA and inhibit the invasive capacity of 3D prostate cancer tumoursJames C Evans, Meenakshi Malhotra, Katrina Sweeney, et al.
The Prostate|May 27, 2010
Relaxin drives Wnt signaling through upregulation of PCDHY in prostate cancerVanessa C Thompson, Antonio Hurtado-Coll, Dmitry Turbin, et al.
Journal of Natural Products|July 22, 2020
Synthesis of a Unique Psammaplysin F Library and Functional Evaluation in Prostate Cancer Cells by Multiparametric Quantitative Single Cell ImagingRohitesh Kumar, Charles L Bidgood, Claire Levrier, et al.
Cell Cycle (Georgetown, Tex.)|July 28, 2017
Discovery of thalicthuberine as a novel antimitotic agent from nature that disrupts microtubule dynamics and induces apoptosis in prostate cancer cellsClaire Levrier, Anja Rockstroh, Brian Gabrielli, et al.
Cancer Research|March 18, 2004
Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independenceSusan L Ettinger, Richard Sobel, Tanis G Whitmore, et al.
Oncotarget|January 7, 2016
The ascidian natural product eusynstyelamide B is a novel topoisomerase II poison that induces DNA damage and growth arrest in prostate and breast cancer cellsMichelle S Liberio, Martin C Sadowski, Rohan A Davis, et al.
Molecular Cancer Therapeutics|October 21, 2016
6α-Acetoxyanopterine: A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer CellsClaire Levrier, Martin C Sadowski, Anja Rockstroh, et al.
The Journal of Steroid Biochemistry and Molecular Biology|May 16, 2009
Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenograftsJennifer A Locke, Colleen C Nelson, Hans H Adomat, et al.
Cell Death & Disease|July 18, 2024
Targeting valine catabolism to inhibit metabolic reprogramming in prostate cancerCharles L Bidgood, Lisa K Philp, Anja Rockstroh, et al.
Pageof 12

Showing results (41-50 of 115) with videos related to

Sort By:
Pageof 12
Oncotarget|October 15, 2014
The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate cancerMartin C Sadowski, Rebecca H Pouwer, Jennifer H Gunter, et al.
International Journal of Pharmaceutics|September 17, 2017
Folate-targeted amphiphilic cyclodextrin nanoparticles incorporating a fusogenic peptide deliver therapeutic siRNA and inhibit the invasive capacity of 3D prostate cancer tumoursJames C Evans, Meenakshi Malhotra, Katrina Sweeney, et al.
The Prostate|May 27, 2010
Relaxin drives Wnt signaling through upregulation of PCDHY in prostate cancerVanessa C Thompson, Antonio Hurtado-Coll, Dmitry Turbin, et al.
Journal of Natural Products|July 22, 2020
Synthesis of a Unique Psammaplysin F Library and Functional Evaluation in Prostate Cancer Cells by Multiparametric Quantitative Single Cell ImagingRohitesh Kumar, Charles L Bidgood, Claire Levrier, et al.
Cell Cycle (Georgetown, Tex.)|July 28, 2017
Discovery of thalicthuberine as a novel antimitotic agent from nature that disrupts microtubule dynamics and induces apoptosis in prostate cancer cellsClaire Levrier, Anja Rockstroh, Brian Gabrielli, et al.
Cancer Research|March 18, 2004
Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independenceSusan L Ettinger, Richard Sobel, Tanis G Whitmore, et al.
Oncotarget|January 7, 2016
The ascidian natural product eusynstyelamide B is a novel topoisomerase II poison that induces DNA damage and growth arrest in prostate and breast cancer cellsMichelle S Liberio, Martin C Sadowski, Rohan A Davis, et al.
Molecular Cancer Therapeutics|October 21, 2016
6α-Acetoxyanopterine: A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer CellsClaire Levrier, Martin C Sadowski, Anja Rockstroh, et al.
The Journal of Steroid Biochemistry and Molecular Biology|May 16, 2009
Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenograftsJennifer A Locke, Colleen C Nelson, Hans H Adomat, et al.
Cell Death & Disease|July 18, 2024
Targeting valine catabolism to inhibit metabolic reprogramming in prostate cancerCharles L Bidgood, Lisa K Philp, Anja Rockstroh, et al.
Pageof 12